Opus Genetics (IRD) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Opus Genetics (IRD) has outperformed PepGen (PEPG) over the past year, gaining 108.9% versus a loss of 32.0%. Opus Genetics is the larger company by market cap ($385.7 million vs $356.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRD | PEPG |
|---|---|---|
| Share price | $3.99 | $3.78 |
| Market cap | $385.65M | $356.31M |
| 1-day change | -2.21% | -3.82% |
| YTD return | +98.51% | -41.94% |
| 1-year return | +108.90% | -32.01% |
| 5-year return | -8.28% | — |
| EPS (TTM) | $-1.48 | $-0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.20M | — |
| Revenue growth (YoY) | +29.15% | — |
| Net income (latest FY) | $-49.59M | $-89.66M |
| Operating margin | -271.90% | — |
| Net margin | -349.33% | — |
| 52-week high | $7.07 | $7.80 |
| 52-week low | $1.88 | $1.31 |
| Distance from 52-week high | -43.56% | -51.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +249.37% | +263.76% |
| Average volume | 2.56M | 3.26M |
| Shares outstanding | 96.65M | 94.26M |
| Employees | 27 | 53 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRD has outperformed PEPG by 140.9 percentage points over the past year.
About Opus Genetics
IRD stock →Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 53 employees
IRD vs PEPG FAQ
Which is bigger, Opus Genetics or PepGen?
Opus Genetics (IRD) is larger, with a market capitalization of $385.65M compared with $356.31M for PepGen (PEPG).
Which stock has performed better over the past year, IRD or PEPG?
IRD returned +108.90% over the past 12 months, compared with -32.01% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Opus Genetics and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.